Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population.

Hambardzumyan K, Hermanrud C, Marits P, Vivar N, Ernestam S, Wallman JK, van Vollenhoven RF, Fogdell-Hahn A, Saevarsdottir S; SWEFOT study group.

Scand J Rheumatol. 2019 Jun 27:1-5. doi: 10.1080/03009742.2019.1602670. [Epub ahead of print]

PMID:
31244356
2.

Different Interferon Beta Preparations Induce the Same Qualitative Immune Response in Human Skin.

Hermanrud C, van Capel TMM, Auer M, Karrenbauer V, Deisenhammer F, de Jong EC, Fogdell-Hahn A.

J Interferon Cytokine Res. 2019 May;39(5):302-313. doi: 10.1089/jir.2018.0038. Epub 2019 Mar 8.

PMID:
30848986
3.

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.

Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium.

J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.

PMID:
30447419
4.

Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.

Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, Dönnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Broët P, Mariette X; ABIRISK Consortium.

Semin Arthritis Rheum. 2019 Jun;48(6):967-975. doi: 10.1016/j.semarthrit.2018.10.006. Epub 2018 Oct 12.

PMID:
30420245
5.

The effect of human herpesvirus 6B infection on the MAPK pathway.

Engdahl E, Niehusmann P, Fogdell-Hahn A.

Virus Res. 2018 Sep 2;256:134-141. doi: 10.1016/j.virusres.2018.08.014. Epub 2018 Aug 18.

PMID:
30130603
6.

Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.

Adriani M, Nytrova P, Mbogning C, Hässler S, Medek K, Jensen PEH, Creeke P, Warnke C, Ingenhoven K, Hemmer B, Sievers C, Lindberg Gasser RL, Fissolo N, Deisenhammer F, Bocskei Z, Mikol V, Fogdell-Hahn A, Kubala Havrdova E, Broët P, Dönnes P, Mauri C, Jury EC; ABIRISK Consortium.

JCI Insight. 2018 Jun 7;3(11). pii: 99274. doi: 10.1172/jci.insight.99274. eCollection 2018 Jun 7.

7.

Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka.

Gamage SMK, Wijeweera I, Adikari SB, Fink K, Hillert J, Fogdell-Hahn A, Sominanda HMA.

Mult Scler Int. 2018 Feb 28;2018:5342936. doi: 10.1155/2018/5342936. eCollection 2018.

8.

Prediction of natalizumab anti-drug antibodies persistency.

Deisenhammer F, Jank M, Lauren A, Sjödin A, Ryner M, Fogdell-Hahn A, Sievers C, Lindberg R, Jensen PE, Sellebjerg F, Christodoulou L, Birchler M, Pallardy M, Auer M, Liblau R; ABIRISK consortium.

Mult Scler. 2019 Mar;25(3):392-398. doi: 10.1177/1352458517753721. Epub 2018 Jan 16.

PMID:
29336205
9.

The Viral Hypothesis of Mesial Temporal Lobe Epilepsy - Is Human Herpes Virus-6 the Missing Link? A systematic review and meta-analysis.

Wipfler P, Dunn N, Beiki O, Trinka E, Fogdell-Hahn A.

Seizure. 2018 Jan;54:33-40. doi: 10.1016/j.seizure.2017.11.015. Epub 2017 Nov 24. Review.

10.

Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.

Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, Piehl F, Fogdell-Hahn A.

Mult Scler. 2018 Aug;24(9):1224-1233. doi: 10.1177/1352458517720044. Epub 2017 Aug 1.

PMID:
28762877
11.

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.

Ingenhoven K, Kramer D, Jensen PE, Hermanrud C, Ryner M, Deisenhammer F, Pallardy M, Menge T, Hartung HP, Kieseier BC, Bertotti E, Creeke P, Fogdell-Hahn A, Warnke C.

Front Neurol. 2017 Jul 6;8:305. doi: 10.3389/fneur.2017.00305. eCollection 2017.

12.

Human Herpesvirus 6B Induces Hypomethylation on Chromosome 17p13.3, Correlating with Increased Gene Expression and Virus Integration.

Engdahl E, Dunn N, Niehusmann P, Wideman S, Wipfler P, Becker AJ, Ekström TJ, Almgren M, Fogdell-Hahn A.

J Virol. 2017 May 12;91(11). pii: e02105-16. doi: 10.1128/JVI.02105-16. Print 2017 Jun 1.

13.

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium.

PLoS One. 2017 Feb 7;12(2):e0170395. doi: 10.1371/journal.pone.0170395. eCollection 2017.

14.

Serum Cotinine Does Not Predict Neutralizing Antibodies Against Interferon Beta in an Austrian MS Cohort.

Auer M, Hegen H, Luft T, Bsteh G, Fogdell-Hahn A, Loercher A, Deisenhammer F.

J Interferon Cytokine Res. 2016 Dec;36(12):667-670. Epub 2016 Oct 19.

PMID:
27918711
15.

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.

Bachelet D, Hässler S, Mbogning C, Link J, Ryner M, Ramanujam R, Auer M, Hyldgaard Jensen PE, Koch-Henriksen N, Warnke C, Ingenhoven K, Buck D, Grummel V, Lawton A, Donnellan N, Hincelin-Mery A, Sikkema D, Pallardy M, Kieseier B, Hemmer B, Hartung HP, Soelberg Sorensen P, Deisenhammer F, Dönnes P, Davidson J, Fogdell-Hahn A, Broët P; ABIRISK Consortium.

PLoS One. 2016 Nov 2;11(11):e0162752. doi: 10.1371/journal.pone.0162752. eCollection 2016.

16.

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.

Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen PS, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, Fogdell-Hahn A; ABIRISK Consortium.

J Immunol Methods. 2016 Mar;430:1-9. doi: 10.1016/j.jim.2016.01.004. Epub 2016 Jan 11.

PMID:
26779831
17.
18.

The Human NK Cell Response to Yellow Fever Virus 17D Is Primarily Governed by NK Cell Differentiation Independently of NK Cell Education.

Marquardt N, Ivarsson MA, Blom K, Gonzalez VD, Braun M, Falconer K, Gustafsson R, Fogdell-Hahn A, Sandberg JK, Michaëlsson J.

J Immunol. 2015 Oct 1;195(7):3262-72. doi: 10.4049/jimmunol.1401811. Epub 2015 Aug 17.

19.

Antidrug Antibodies: B Cell Immunity Against Therapy.

Fogdell-Hahn A.

Scand J Immunol. 2015 Sep;82(3):184-90. doi: 10.1111/sji.12327. Review.

20.

Modulatory effects on dendritic cells by human herpesvirus 6.

Gustafsson R, Svensson M, Fogdell-Hahn A.

Front Microbiol. 2015 Apr 30;6:388. doi: 10.3389/fmicb.2015.00388. eCollection 2015. Review.

21.

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium.

Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, Carini C, Creeke P, Davidson J, De Vries N, Finco D, Fogdell-Hahn A, Havrdova E, Hincelin-Mery A, C Holland M, H Jensen PE, Jury EC, Kirby H, Kramer D, Lacroix-Desmazes S, Legrand J, Maggi E, Maillère B, Mariette X, Mauri C, Mikol V, Mulleman D, Oldenburg J, Paintaud G, R Pedersen C, Ruperto N, Seitz R, Spindeldreher S, Deisenhammer F; ABIRISK Consortium.

Clin Exp Immunol. 2015 Sep;181(3):385-400. doi: 10.1111/cei.12652. Epub 2015 Jul 2. Review.

22.

Interferon beta treatment of multiple sclerosis increases serum interleukin-7.

Lundström W, Hermanrud C, Sjöstrand M, Brauner S, Wahren-Herlenius M, Olsson T, Karrenbauer V, Hillert J, Fogdell-Hahn A.

Mult Scler. 2014 Nov;20(13):1727-36. doi: 10.1177/1352458514532700. Epub 2014 May 12.

PMID:
24821684
23.

The case for measuring anti-drug antibodies in people with multiple sclerosis.

Lundkvist Ryner M, Farrell RA, Fogdell-Hahn A.

Expert Rev Clin Immunol. 2014 Jun;10(6):697-9. doi: 10.1586/1744666X.2014.914852. Epub 2014 Apr 30.

PMID:
24780058
24.

JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants.

Sundqvist E, Buck D, Warnke C, Albrecht E, Gieger C, Khademi M, Lima Bomfim I, Fogdell-Hahn A, Link J, Alfredsson L, Søndergaard HB, Hillert J; International Multiple Sclerosis Genetics Consortium, Oturai AB, Hemmer B, Kockum I, Olsson T.

PLoS Pathog. 2014 Apr 24;10(4):e1004084. doi: 10.1371/journal.ppat.1004084. eCollection 2014 Apr. Erratum in: PLoS Pathog. 2014 Sep;10(9):e1004430. Hemme, Bernhard [corrected to Hemmer, Bernhard].

25.

HLA-A(∗)02, gender and tobacco smoking, but not multiple sclerosis, affects the IgG antibody response against human herpesvirus 6.

Engdahl E, Gustafsson R, Ramanujam R, Sundqvist E, Olsson T, Hillert J, Alfredsson L, Kockum I, Fogdell-Hahn A.

Hum Immunol. 2014 Jun;75(6):524-30. doi: 10.1016/j.humimm.2014.03.001. Epub 2014 Mar 22.

PMID:
24662416
26.

Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.

Link J, Lundkvist Ryner M, Fink K, Hermanrud C, Lima I, Brynedal B, Kockum I, Hillert J, Fogdell-Hahn A.

PLoS One. 2014 Mar 7;9(3):e90479. doi: 10.1371/journal.pone.0090479. eCollection 2014.

27.

Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point.

Hermanrud C, Ryner ML, Engdahl E, Fogdell-Hahn A.

J Interferon Cytokine Res. 2014 Jul;34(7):498-504. doi: 10.1089/jir.2013.0097. Epub 2014 Jan 20.

PMID:
24444338
28.

Smokers run increased risk of developing anti-natalizumab antibodies.

Hedström AK, Alfredsson L, Lundkvist Ryner M, Fogdell-Hahn A, Hillert J, Olsson T.

Mult Scler. 2014 Jul;20(8):1081-5. doi: 10.1177/1352458513515086. Epub 2013 Dec 5.

PMID:
24311118
29.

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.

Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, Hartung HP, Fogdell-Hahn A, Adams O, Kieseier BC.

Neurology. 2013 Oct 15;81(16):1400-8. doi: 10.1212/WNL.0b013e3182a84101. Epub 2013 Sep 18.

PMID:
24049136
30.

Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a.

Hedström AK, Ryner M, Fink K, Fogdell-Hahn A, Alfredsson L, Olsson T, Hillert J.

Mult Scler. 2014 Apr;20(4):445-50. doi: 10.1177/1352458513498635. Epub 2013 Aug 7.

PMID:
23924603
31.

Incidence of human herpesvirus 6 in clinical samples from Swedish patients with demyelinating diseases.

Gustafsson R, Reitsma R, Strålfors A, Lindholm A, Press R, Fogdell-Hahn A.

J Microbiol Immunol Infect. 2014 Oct;47(5):418-21. doi: 10.1016/j.jmii.2013.03.009. Epub 2013 May 31.

32.

Human herpesvirus 6A partially suppresses functional properties of DC without viral replication.

Gustafsson RK, Engdahl EE, Hammarfjord O, Adikari SB, Lourda M, Klingström J, Svensson M, Fogdell-Hahn A.

PLoS One. 2013;8(3):e58122. doi: 10.1371/journal.pone.0058122. Epub 2013 Mar 5.

33.

First therapeutic use of Artesunate in treatment of human herpesvirus 6B myocarditis in a child.

Hakacova N, Klingel K, Kandolf R, Engdahl E, Fogdell-Hahn A, Higgins T.

J Clin Virol. 2013 Jun;57(2):157-60. doi: 10.1016/j.jcv.2013.02.005. Epub 2013 Mar 6.

PMID:
23473961
34.

Changes to anti-JCV antibody levels in a Swedish national MS cohort.

Warnke C, Ramanujam R, Plavina T, Bergström T, Goelz S, Subramanyam M, Kockum I, Rahbar A, Kieseier BC, Holmén C, Olsson T, Hillert J, Fogdell-Hahn A.

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1199-205. doi: 10.1136/jnnp-2012-304332. Epub 2013 Mar 5.

35.

Fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies.

Svenningsson A, Dring AM, Fogdell-Hahn A, Jones I, Engdahl E, Lundkvist M, Brännström T, Gilthorpe JD.

Neurology. 2013 Mar 5;80(10):965-7. doi: 10.1212/WNL.0b013e3182840be3. Epub 2013 Feb 6. No abstract available.

PMID:
23390173
36.

Development and validation of a Q-PCR based TCID50 method for human herpesvirus 6.

Gustafsson RK, Engdahl EE, Fogdell-Hahn A.

Virol J. 2012 Dec 18;9:311. doi: 10.1186/1743-422X-9-311.

37.

Characterization of anti-natalizumab antibodies in multiple sclerosis patients.

Lundkvist M, Engdahl E, Holmén C, Movérare R, Olsson T, Hillert J, Fogdell-Hahn A.

Mult Scler. 2013 May;19(6):757-64. doi: 10.1177/1352458512462920. Epub 2012 Oct 8.

PMID:
23045379
38.

3rd Nordic Meeting on Genetics and Pathogenesis of Inflammatory Diseases.

Wahren-Herlenius M, Fogdell-Hahn A.

Scand J Immunol. 2012 Aug;76(2):75-6. doi: 10.1111/j.1365-3083.2012.02753.x. No abstract available.

39.

Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.

Jungedal R, Lundkvist M, Engdahl E, Ramanujam R, Westerlind H, Sominanda A, Hillert J, Fogdell-Hahn A.

Mult Scler. 2012 Dec;18(12):1775-81. doi: 10.1177/1352458512446036. Epub 2012 May 2.

PMID:
22551640
40.

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis.

Warnke C, Stüve O, Hartung HP, Fogdell-Hahn A, Kieseier BC.

Neuropsychiatr Dis Treat. 2011;7:519-27. doi: 10.2147/NDT.S10481. Epub 2011 Sep 8.

41.

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.

Sørensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler C, Sellebjerg F, Koch-Henriksen N, Fogdell-Hahn A, Myhr KM, Hillert J, Gold R.

Mult Scler. 2011 Sep;17(9):1074-8. doi: 10.1177/1352458511404271. Epub 2011 Apr 20.

PMID:
21511692
42.

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T.

Mult Scler. 2011 Jun;17(6):708-19. doi: 10.1177/1352458510394701. Epub 2011 Jan 12.

PMID:
21228027
43.

Interleukin-2 gene expression in different phases of episodic cluster headache--a pilot study.

Steinberg A, Sjöstrand C, Sominanda A, Fogdell-Hahn A, Remahl AI.

Acta Neurol Scand. 2011 Aug;124(2):130-4. doi: 10.1111/j.1600-0404.2010.01434.x. Epub 2010 Sep 29.

PMID:
20880293
44.

Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.

Sominanda A, Lundkvist M, Fogdell-Hahn A, Hemmer B, Hartung HP, Hillert J, Menge T, Kieseier BC.

Arch Neurol. 2010 Sep;67(9):1095-101. doi: 10.1001/archneurol.2010.218.

PMID:
20837854
45.

Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.

Lundkvist M, Greiner E, Hillert J, Fogdell-Hahn A.

Mult Scler. 2010 Jul;16(7):796-800. doi: 10.1177/1352458510373112. Epub 2010 Jun 9.

PMID:
20534645
46.

Impression of clinical worsening fails to predict interferon-beta neutralizing antibody status.

Rot U, Sominanda A, Fogdell-Hahn A, Hillert J.

J Int Med Res. 2008 Nov-Dec;36(6):1418-25.

PMID:
19094453
47.

Neutralizing antibodies against interferon β: fluctuation is modest and titre dependent.

Sominanda A, Hillert J, Fogdell-Hahn A.

Eur J Neurol. 2009 Jan;16(1):21-6. doi: 10.1111/j.1468-1331.2008.02264.x. Epub 2008 Aug 23.

PMID:
18727672
48.

Comparative study of four different assays for the detection of binding antibodies against interferon-beta.

Gneiss C, Brugger M, Millonig A, Fogdell-Hahn A, Rudzki D, Hillert J, Berger T, Reindl M, Deisenhammer F.

Mult Scler. 2008 Jul;14(6):830-6. doi: 10.1177/1352458508089228. Epub 2008 Jun 5.

PMID:
18535018
49.

Confirmed primary HHV-6 infection in children with suspected encephalitis.

Virtanen JO, Herrgård E, Valmari P, Ahlqvist J, Fogdell-Hahn A, Vaheri A, Koskiniemi M.

Neuropediatrics. 2007 Dec;38(6):292-7. doi: 10.1055/s-2008-1065357.

PMID:
18461505
50.

Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.

Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G, Hartung HP, Hemmer B, Hillert J, Kappos L, Killestein J, Lindberg R, Montalban X, Polman C, Sorensen PS; European NABINMS Consortium.

J Int Med Res. 2008 Jan-Feb;36(1):204-8; author reply 208-10. No abstract available.

PMID:
18230281

Supplemental Content

Loading ...
Support Center